Mesoblast Limited (MESO)
(Real Time Quote from BATS)
$6.82 USD
+0.41 (6.40%)
Updated Sep 20, 2024 03:02 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MESO 6.82 +0.41(6.40%)
Will MESO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MESO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MESO
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
MESO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
5 Stocks to Ride the Santa Claus Rally
Other News for MESO
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Mesoblast just upgraded at Jefferies, here's why
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
Mesoblast GAAP EPS of -$0.09 beats by $0.63, revenue of $5.9M misses by $1.71M
Here's the major earnings after the close today